KMDAHealthcare · Drug Manufacturers - Specialty & GenericThe 3 Wall Street analysts covering Kamada Ltd. hold a median 12-month price target of $13 — +89.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 12 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Kamada Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (41): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on KMDA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +89.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | $11 → $13 |
| 15 May 2025 | Benchmark | Reiterates | Buy | — |
| 21 Mar 2025 | Benchmark | Initiates | Buy | — |
| 6 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 July 2024 | Stifel | Initiates | Buy | — |
| 9 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Feb 2018 | Chardan Capital | Initiates | Buy | — |
| 13 Nov 2015 | Jefferies | Maintains | Buy | — |
| 25 June 2013 | Jefferies | Initiates | Buy | — |
| 25 June 2013 | Morgan Stanley | Initiates | Equal-Weight | — |
| 25 June 2013 | Oppenheimer | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KMDA appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 40% of US stocks
Cheaper than 51% of US stocks
Cheaper than 55% of US stocks
Cheaper than 42% of US stocks
Higher than 34% of US stocks
Higher than 41% of US stocks
Higher than 53% of US stocks
Higher than 73% of US stocks
Higher than 72% of US stocks
Higher than 59% of US stocks
Higher than 72% of US stocks
Higher than 93% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Kamada Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the earnings call transcript for Kamada Ltd.'s second quarter of 2026. The item consists solely of the headline and source attribution for this transcript release.
Why it matters — A KMDA watcher would care because the release of the Q2 2026 earnings call transcript provides access to management's commentary on the company's quarterly performance.
Kamada reported record revenue and adjusted EBITDA for Q2 and the first half of 2026, driven by higher sales of its specialty plasma-derived products, and reiterated its full-year guidance. The company also expects initial sales under a new plasma supply agreement to begin in the fourth quarter.
Why it matters — A KMDA watcher would care because record revenue and EBITDA, combined with an upcoming new plasma supply agreement, signal strong operational momentum for the company.
Zacks Investment Research reported that Kamada's Q2 2026 revenue and EPS will be compared against Wall Street estimates and prior-year figures to assess its quarterly performance.
Why it matters — KMDA watchers can gauge how the company's key financial metrics stack up against analyst expectations and year-ago results, offering a snapshot of its operational trajectory.
Kamada reported quarterly earnings of $0.16 per share, surpassing the Zacks Consensus Estimate of $0.12 per share and up from $0.13 per share a year ago. Revenue also exceeded estimates.
Why it matters — A KMDA watcher would care because the company beat analyst expectations on both earnings and revenue in the latest quarter.
Kamada reported record-high financial results for the first half and second quarter of 2026 (periods ended June 30, 2026), describing double-digit profitable growth as the strongest in the company's history. The company also affirmed its 2026 annual guidance.
Why it matters — For Kamada watchers, this confirms the company's strongest-ever financial performance in the latest reporting periods and that management is standing by its full-year outlook.
The 3 Wall Street analysts covering Kamada Ltd. have a median 12-month price target of $13, with estimates ranging from $11 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Kamada Ltd., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kamada Ltd. 87 out of 100 across roughly 4,600 US stocks as at 12 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Aug 2026, Kamada Ltd. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +89.0% from the last close, and Ticker Nerd's factor model ranks Kamada Ltd. 87 out of 100 as at 12 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Kamada Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KMDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $15 over the next 12 months.
Kamada Ltd. returned -5.4% over the 12 months to 12 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Kamada Ltd. is a biopharmaceutical company specializing in the development, production, and marketing of specialty plasma-derived protein therapeutics.
The most recent item we track (Seeking Alpha, 12 Aug 2026): "Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript". Seeking Alpha published the earnings call transcript for Kamada Ltd.'s second quarter of 2026. The item consists solely of the headline and source attribution for this transcript release.
Kamada Ltd. is a biopharmaceutical company specializing in the development, production, and marketing of specialty plasma-derived protein therapeutics. Its primary purpose is to provide innovative medical solutions for unmet clinical needs, particularly in the fields of immunology, respiratory diseases, and critical care. Kamada’s portfolio includes a range of products, such as Alpha-1 Antitrypsin (AAT) for the treatment of Alpha-1 Antitrypsin Deficiency and a variety of hyperimmunoglobulins targeting infectious diseases. The company significantly impacts the healthcare sector by offering therapies that address rare and life-threatening conditions, thus contributing to advancements in patient care and quality of life. Kamada Ltd.'s role in the financial markets is notable for its focus on R&D-driven growth, with an array of advanced products in its pipeline aimed at broadening therapeutic applications. Headquartered in Israel, Kamada distributes its products internationally, collaborating with multinational healthcare companies and leveraging a robust supply chain for global market access. Its contributions to the biopharmaceutical industry highlight its commitment to expanding the reach of essential therapeutic options worldwide.
462 employees · Israel · https://www.kamada.com